Effect of folic acid supplementation on the change of plasma S-adenosylhomocysteine level in Chinese hypertensive patients: a randomized, double-blind, controlled clinical trial.

The relationship between folic acid and S-adenosylhomocysteine (SAH) is controversial. This study aims to explore the effect of different doses of folic acid supplementation on SAH levels in hypertensive patients and the modification of methylene-tetrahydrofolate reductase (MTHFR) C677T gene polymorphism. A randomized, double-blind, controlled clinical trial was conducted. Hypertensive patients aged 45-75 years without a history of stroke and cardiovascular disease were selected, who were randomly assigned to one of 8 dose groups. This trial has been registered with Trial Number: ChiCTR1800016135. In the total population, folic acid supplementation of 0.4-2.0 mg/day had no effect on SAH level (ß = 0.47, 95% CI: -0.86-1.79, p = 0.491), while folic acid supplementation of 2.4 mg/day significantly increased SAH level (ß = 1.93, 95% CI: 0.22-3.64, p = 0.027). Stratified analysis found that MTHFR C677T genotype CC supplemented with 2.4 mg/day folic acid had no effect on SAH level (ß = 0.30, 95% CI: -2.74-3.34, p = 0.847), while CT and TT genotype supplemented with 2.4 mg/day folic acid showed a significant increase in SAH level (CT: ß = 2.98, 95% CI: 0.34-5.62, p = 0.027; TT: ß = 3.00, 95% CI: -0.51-6.51, p = 0.095; CT combined with TT: ß = 2.99, 95% CI: 0.90-5.09, p = 0.005). In conclusion, supplementation of 2.4 mg/day folic acid can lead to increased SAH levels, especially in MTHFR C677T genotype CT and TT.

[Effects of different anesthesia and analgesia on erythrocyte immune function of patients with ovarian benign tumor treated by laparoscopic therapeutic].

AIM: To investigate the effects of different anesthesia and analgesia on erythrocyte immune function of patients with ovarian benign tumor treated by laparoscopic therapeutic. METHODS: 120 patients with ovarian benign tumor treated by laparoscopic therapeutic were randomly divided into two groups with 60 cases each.In group A, patients received general anesthesia eombined with thoracic epidural anesthesia during surgery, patients in group B received general anesthesia. The cervical venous blood samples were obtained at the following time points: before induction of anesthesia(T0), 30 min after anesthesia (T1), 1 h during operation (T2), 24 h after operation (T3), 48 h after operation (T4) and 72 h after operation (T5).RRCR, RRICR and RTRR were measured at different time points. RESULTS: RRCR, RRICR and RTRR in two groups decreased significantly from T1(P<0.05). RRCR in two groups was on the low-water mark at T4 and RRICR, RTRR was on the low-water mark at T3.There were no significantly different of RRCR, RRICR and RTRR in two groups at T0. There were significantly different of RRCR, RRICR and RTRR in two groups from T1 to T4(P<0.05), the increase in group A was less than that in group B(P<0.05). CONCLUSION: Anesthesia may harm on erythroeyte immune function of patients with ovarian benign tumor treated by laparoscopic therapeutic. The effect of general anesthesia combined with thoraeic epidural anesthesia on erythrocyte immune function was less.